-
公开(公告)号:FR2918369B1
公开(公告)日:2009-08-28
申请号:FR0704746
申请日:2007-07-02
Applicant: SERVIER LAB
Inventor: YOUS SAID , ETTAOUSSI MOHAMED , SABAOUNI AHMED , BERTHELOT PASCAL , SPEDDING MICHAEL , DELAGRANGE PHILIPPE , CAIGNARD DANIEL HENRI , MILLAN MARK
IPC: C07C233/22 , A61K31/165 , A61P1/00 , A61P9/00 , A61P15/00 , A61P25/00 , A61P35/00 , C07C231/14
-
82.
公开(公告)号:AU2005232420B8
公开(公告)日:2009-06-11
申请号:AU2005232420
申请日:2005-03-30
Inventor: PENICAUD LUC , DACQUET CATHERINE , CAIGNARD DANIEL-HENRI , BERTHELOT PASCAL , CASTEILLA LOUIS
IPC: A61K31/15 , A61K9/20 , A61K31/428
Abstract: A pharmaceutical composition for treatment of obesity associated with lipid and carbohydrate metabolism comprising (i) a substance which is useful in promoting lipid and carbohydrate metabolism, (ii) an antioxidant agent and, optionally, (iii) a pharmaceutically acceptable carrier or excipient, wherein the substance which promotes lipid and carbohydrate metabolism and the antioxidant agent are present in therapeutically effective dosages. Methods which are useful in treating conditions associated with obesity.
-
公开(公告)号:HRP20090018T3
公开(公告)日:2009-02-28
申请号:HRP20090018
申请日:2009-01-14
Applicant: SERVIER LAB
Inventor: HURTEVENT AURULIE , CARATO PASCAL , LEBEGUE NICOLAS , LECLERC VURONIQUE , BERTHELOT PASCAL , DACQUET CATHERINE , KTORZA ALAIN , CAIGNARD DANIEL-HENRI
IPC: C07D279/16 , A61K31/538 , A61K31/5415 , A61P3/06 , A61P3/10 , C07D265/36
Abstract: Heterocyclic oxime derivatives (I), their enantiomers, diastereomers and their acid or basic addition salts are new. Heterocyclic oxime derivatives of formula (I), their enantiomers, diastereomers and their acid or basic addition salts are new. X : O or S; A : 1-6C alkyl (where CH 2 can be replaced by heteroatom (O or S), NR a or a phenyl or naphthyl group); R aH or 1-6C alkyl; R 1>, R 2>, R, R1 : H, 1-6C ((hetero)aryl)alkyl, 2-6C ((hetero)aryl)alkenyl, 2-6C ((hetero)aryl)alkynyl, (hetero)aryl, 3-8C cycloalkyl-1-6C alkyl or polyhalo-1-6C alkyl; either R 3>, R 4>H, halo, R, OR or NRR1; or -C-R 3>-R 4>-C- : 5-6 membered ring (containing heteroatom (O, S or N); B 1>1-6C alkyl, 2-6C alkenyl (both optionally substituted by -CHR 5>R 6> or R 7>), -CHR 5>R 6> or R 7>; R 5>-C(=Z)-OR, -C(=Z)-NRR1, -N(R)-C(=Z)-R1 or -N(R)-C(=Z)-OR1; Z : O or S; R 6>(hetero)aryl, (hetero)aryl-1-6C alkyl, CN, tetrazole, OR, NRR1, -N(R)-C(=Z)-R1, -N(R)-C(=Z)-OR1 or -N(R)-C(=Z)-R; R 7>CN, tetrazole, -N(R)-C(=Z)-R1, -N(R)-C(=Z)-OR1 or -O-(CH 2) n-C(R 8>R 9>)-COOR; n : 1-6; and R 8>, R 9>H or 1-6C alkyl. Provided that both R 8> and R 9> are not simultaneously H. Provided that: the oxime R 1>-C(=N-OR 2>)- can be the Z or E configuration; the aryl are phenyl, naphthyl or biphenyl, which can be partially hydrogenated; the heteroaryl are 5-10 membered mono or bicylic aromatic, where the bicyclics can partially be hydrogenated, and containing 1-3 heteroatom (O, N or S); the (hetero)aryl are optionally substituted by 1-3 of 1-6C (polyhalo)alkyl, 1-6C alkoxy, OH, carboxy, 1-6C alkoxycarbonyl, 1-6C acyloxy, formyl, 1-6C acyl, aryl, NR bR c, amido, nitro, CN or halo, where R b, R c are H, 1-6C alkyl or (hetero)aryl. Independent claims are included for: (1) the preparations of (I); (2) a composition (X) comprising (I) an antioxidant agent. [Image] ACTIVITY : Antidiabetic; Antilipemic; Analgesic; Antianginal; Cardiant; Vasotropic; Cardiovascular-Gen.; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Osteopathic; Gastrointestinal-Gen.; Antiinflammatory; Antiarteriosclerotic; Anorectic; Anabolic; Eating-Disorders-Gen.; Neuroprotective; Cytostatic; Endocrine-Gen.; Neuroleptic. The antidiabetic and hypolipidemic effect of (I) was tested in female mouse. The results showed that (I) exhibited a very good capacity to reduce the glycemia compared with the effects obtained with Rosiglitazone. MECHANISM OF ACTION : Angiogenesis inhibitor.
-
公开(公告)号:FR2918371A1
公开(公告)日:2009-01-09
申请号:FR0704749
申请日:2007-07-02
Applicant: SERVIER LAB
Inventor: YOUS SAID , ETTAOUSSI MOHAMED , SABAOUNI AHMED , BERTHELOT PASCAL , SPEDDING MICHAEL , DELAGRANGE PHILIPPE , CAIGNARD DANIEL HENRI , MILLAN MARK
IPC: C07C233/22 , A61K31/165 , A61P1/00 , A61P9/00 , A61P15/00 , A61P25/00 , A61P35/00 , C07C231/14
Abstract: Composés de formule (I) : dans laquelle :R1 représente un alkyle, alkényle, halogénoalkyle, polyhalogénoalkyle, cycloalkyle, cycloalkylalkyle, aryle, arylalkyle, hétéroaryle ou hétéroarylalkyleR2 et R3 représentent un atome d'hydrogène ou un groupement alkyleMédicaments.
-
公开(公告)号:FR2918368A1
公开(公告)日:2009-01-09
申请号:FR0704745
申请日:2007-07-02
Applicant: SERVIER LAB
Inventor: YOUS SAID , ETTAOUSSI MOHAMED , SABAOUNI AHMED , BERTHELOT PASCAL , SPEDDING MICHAEL , DELAGRANGE PHILIPPE , CAIGNARD DANIEL HENRI , MILLAN MARK
IPC: C07C231/12 , A61K31/165 , A61P15/00 , A61P25/00 , A61P35/00 , C07C233/13
Abstract: Composé de formule (I) : Médicaments.
-
公开(公告)号:DE602006003630D1
公开(公告)日:2008-12-24
申请号:DE602006003630
申请日:2006-01-26
Applicant: SERVIER LAB
Inventor: HURTEVENT AURELIE , L HELGOUAL CH JEAN-MARTIAL , CARATO PASCAL , LEBEGUE NICOLAS , LECLERC VERONIQUE , BERTHELOT PASCAL , DACQUET CATHERINE , KTORZA ALAIN , CAIGNARD DANIEL-HENRI
IPC: C07D279/16 , A61K31/538 , A61K31/5415 , A61P3/06 , A61P3/10 , C07D265/36
Abstract: Heterocyclic oxime derivatives (I), their enantiomers, diastereomers and their acid or basic addition salts are new. Heterocyclic oxime derivatives of formula (I), their enantiomers, diastereomers and their acid or basic addition salts are new. X : O or S; A : 1-6C alkyl (where CH 2 can be replaced by heteroatom (O or S), NR a or a phenyl or naphthyl group); R aH or 1-6C alkyl; R 1>, R 2>, R, R1 : H, 1-6C ((hetero)aryl)alkyl, 2-6C ((hetero)aryl)alkenyl, 2-6C ((hetero)aryl)alkynyl, (hetero)aryl, 3-8C cycloalkyl-1-6C alkyl or polyhalo-1-6C alkyl; either R 3>, R 4>H, halo, R, OR or NRR1; or -C-R 3>-R 4>-C- : 5-6 membered ring (containing heteroatom (O, S or N); B 1>1-6C alkyl, 2-6C alkenyl (both optionally substituted by -CHR 5>R 6> or R 7>), -CHR 5>R 6> or R 7>; R 5>-C(=Z)-OR, -C(=Z)-NRR1, -N(R)-C(=Z)-R1 or -N(R)-C(=Z)-OR1; Z : O or S; R 6>(hetero)aryl, (hetero)aryl-1-6C alkyl, CN, tetrazole, OR, NRR1, -N(R)-C(=Z)-R1, -N(R)-C(=Z)-OR1 or -N(R)-C(=Z)-R; R 7>CN, tetrazole, -N(R)-C(=Z)-R1, -N(R)-C(=Z)-OR1 or -O-(CH 2) n-C(R 8>R 9>)-COOR; n : 1-6; and R 8>, R 9>H or 1-6C alkyl. Provided that both R 8> and R 9> are not simultaneously H. Provided that: the oxime R 1>-C(=N-OR 2>)- can be the Z or E configuration; the aryl are phenyl, naphthyl or biphenyl, which can be partially hydrogenated; the heteroaryl are 5-10 membered mono or bicylic aromatic, where the bicyclics can partially be hydrogenated, and containing 1-3 heteroatom (O, N or S); the (hetero)aryl are optionally substituted by 1-3 of 1-6C (polyhalo)alkyl, 1-6C alkoxy, OH, carboxy, 1-6C alkoxycarbonyl, 1-6C acyloxy, formyl, 1-6C acyl, aryl, NR bR c, amido, nitro, CN or halo, where R b, R c are H, 1-6C alkyl or (hetero)aryl. Independent claims are included for: (1) the preparations of (I); (2) a composition (X) comprising (I) an antioxidant agent. [Image] ACTIVITY : Antidiabetic; Antilipemic; Analgesic; Antianginal; Cardiant; Vasotropic; Cardiovascular-Gen.; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Osteopathic; Gastrointestinal-Gen.; Antiinflammatory; Antiarteriosclerotic; Anorectic; Anabolic; Eating-Disorders-Gen.; Neuroprotective; Cytostatic; Endocrine-Gen.; Neuroleptic. The antidiabetic and hypolipidemic effect of (I) was tested in female mouse. The results showed that (I) exhibited a very good capacity to reduce the glycemia compared with the effects obtained with Rosiglitazone. MECHANISM OF ACTION : Angiogenesis inhibitor.
-
公开(公告)号:MX2008011449A
公开(公告)日:2008-09-24
申请号:MX2008011449
申请日:2007-03-05
Applicant: SERVIER LAB
Inventor: CAIGNARD DANIEL-HENRI , BERTHELOT PASCAL , DACQUET CATHERINE , LEBEGUE NICOLAS , CARATO PASCAL , KTORZA ALAIN , HURTEVENT AURELIE , LECLERC VERONIQUE , L'HELGOUAL CH JEAN-MARTIAL , NAOUR MORGAN LE
IPC: C07D277/68 , A61K31/428 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: La invención se relaciona con compuestos de fórmula (I) donde R1 representa un grupo cicloalquilo (C3- C8), R2 representa un grupo de fórmula (II) como se define en la descripción, X representa un átomo de oxígeno, o un grupo N-OR´ donde R´ representa un átomo de hidrógeno, un grupo alquilo lineal o ramificado (C1-C6), o un grupo arilo o arilalquilo lineal o ramificado (C1-C6) como agentes hipoglicémicos o hipolipidémicos. (ver fórmula I).
-
公开(公告)号:AR061741A1
公开(公告)日:2008-09-17
申请号:ARP070102913
申请日:2007-06-29
Applicant: SERVIER LAB
Inventor: YOUS SAID , PERES BASILE , SABAOUNI AHMED , BERTHELOT PASCAL , SPEDDING MICHAEL , DELAGRANGE PHILIPPE , CAIGNARD DANIEL-HENRI , MILLAN MARK
IPC: C07C233/18 , A61K31/16 , A61P9/10
Abstract: Reivindicacion 1: Compuesto de formula (1), sus enantiomeros, así como sus sales de adicion a una base farmacéuticamente aceptable.
-
公开(公告)号:FR2903404B1
公开(公告)日:2008-08-22
申请号:FR0606247
申请日:2006-07-10
Applicant: SERVIER LAB
Inventor: L'HELGOUAL'CH JEAN MARTIAL , LE NAOUR MORGAN , BERTHELOT PASCAL , LEBEGUE NICOLAS , LECLERC VERONIQUE , CARATO PASCAL , DACQUET CATHERINE , KTORZA ALAIN , CAIGNARD DANIEL HENRI
IPC: C07D277/68 , A61K31/122 , A61K31/428 , A61P3/04 , A61P3/10
-
公开(公告)号:BRPI0702983A
公开(公告)日:2008-02-19
申请号:BRPI0702983
申请日:2007-06-29
Applicant: SERVIER LAB
Inventor: YOUS SAID , PERES BASILE , SABAOUNI AHMED , BERTHELOT PASCAL , SPEDDING MICHAEL , DELAGRANGE PHILIPPE , CAIGNARD DANIEL HENRI , DESROSES MATTHIEU , BOUTIN JEAN-ALBERT , AUDINOT VALERIE
IPC: C07C233/60 , A61K31/165 , A61K31/18 , A61P25/22 , C07C217/60 , C07C231/06 , C07C247/06 , C07C255/33 , C07C275/24 , C07C309/66 , C07D295/10
Abstract: Naphthalenic derivatives (I) and their enantiomers, diastereoisomer or additive salts of acid or base, are new. Naphthalenic derivatives of formula (I) and their enantiomers, diastereoisomer or additive salts of acid or base, are new. R 1R 4or NHR 4; R 41-6C (halo)alkyl, 1-6C alkenyl, polyhalo(1-6C)alkyl, 3-8C cycloalkyl, 3-8C cycloalkyl(1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl or heteroaryl(1-6C)alkyl; R 21-6C alkyl substituted 1-6C alkoxy, OH, OSO 2CH 3, N 3, NRR1a, NHCOR1b or NHSO 2R1b; either R, R1a : H or 1-6C alkyl, 3-8C cycloalkyl, aryl or aryl(1-6C)alkyl; or NRR1a : 5-6 membered ring having another heteroatom e.g. N, O or S; R1b : R; and R 3H, halo, 1-6C alkyl or 1-6C alkenyl. Provided that: when R 1is methyl and R 2is hydroxymethyl, then R 3is not hydrogen; the aryl is phenyl, naphthyl or biphenyl; and the heteroaryl is mono or bicyclic heteroaryl with 1-3 heteroatoms e.g. oxygen, sulfur and nitrogen. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen; Gastrointestinal-Gen; Muscular-Gen; CNS-Gen; Neuroleptic; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Dermatological; Antimigraine; Neuroprotective; Cytostatic; Cerebroprotective; Endocrine-Gen.; Contraceptive. MECHANISM OF ACTION : Melatoninergic receptor agonist. The melatoninergic receptor inhibiting activity of N-[3-methoxy-2-(7-methoxy-1-naphtyl)propyl]acetamide was tested. The result showed that the compound had an inhibition constant (Ki) value of 4.9 mu M.
-
-
-
-
-
-
-
-
-